MassHealth recently announced the following updates to the MassHealth Unified Formulary, effective May 6, 2024. The table below outlines these changes. Tufts Health Together-MassHealth MCO Plan and ACPPs utilize MassHealth’s Unified Formulary for pharmacy medications and select medical benefit drugs. Please keep in mind that updated coverage and criteria will be available on the MassHealth Drug List on or after the effective date.
| Adding to MassHealth Drug List (MHDL) | Agamree (PA); Anzemet tablet (PA); FreeStyle Libre 3 reader (PA, QL); Fruzaqla (PA, QL); Jesduvroq (PA); Likmez (PA); Motpoly XR (PA); Penbraya (QL); Rozlytrek pellet (PA, QL); Sohonos (PA); Suflave (PA); Takhzyro 150 mg/mL (PA); Vanflyta (PA, QL); Xalkori pellet (PA); Vevye (PA, QL); Voquezna (PA, QL); Xdemvy (PA, QL) |
| Adding or updating quantity limit | Marinol; Testosterone 1% gel 2.5 gram packet; testosterone 1.62% gel 1.25 gram packet |
| Adding or updating prior authorization restrictions | Alendronate solution (PA); coenzyme Q10 (PA for 21 years of age and older); Namzaric (PA); tolnaftate liquid (PA) |
| Updating therapeutic class tables | Acromegaly, Carcinoid Syndrome, and Cushing’s Syndrome Agents; Agents Not Otherwise Classified; Alzheimer’s Agents; Androgens; Anti-Allergy and Anti-Inflammatory Agents – Ophthalmic; Antibiotics and Anti-Infectives – Oral and Inhaled; Anticonvulsants; Antidepressants; Antiemetics, Appetite Stimulants, and Anabolics; Antidiabetic Agents; Antifungal Agents – Topical; Antiglaucoma Agents – Ophthalmic; Anti-Hemophilia Agents; Anti-Obesity Agents; Antiparkinsonian Agents; Antipsychotics; Cardiovascular Agents; Antiretroviral/HIV Therapy; Diabetes Medical Supplies and Emergency Treatments; Gastrointestinal Drugs – Antidiarrheals, Constipation, and Miscellaneous Gastrointestinal Agents; Hematologic Agents – Hematopoietic and Miscellaneous Hematologic Agents; Hereditary Angioedema Agents; Immunological Agents; Lipid-Lowering Agents; Nonsteroidal Anti-Inflammatory Drugs; Oncology Agents; Osteoporosis and Bone Metabolism Agents; Pediatric Behavioral Health; Serums, Toxoids, and Vaccines; T-Cell Immunotherapies; Thrombocytopenic Agents |
| Drugs being added to the MassHealth brand name preferred over generic list | Emflaza; Farxiga; Isentress; Marinol; Restasis; Sprycel; Toujeo; Xigduo XR |
| Drugs being removed from the MassHealth brand name preferred over generic list | Fortesta; Kazano; Luzu; Nesina; Oseni; Oxistat cream; Pennsaid; Pristiq; Rapamune solution; Welchol |
| Drugs being locked to the medical benefit (utilization management restrictions may apply) | Elrexfio; Izervay; Mylotarg; Portrazza; Rybrevant; Talvey; Veopoz; Zepzelca; Zilretta |
| Drugs being removed from the medical benefit lock (utilization management restrictions may apply) | Vyvujek |
| Drugs being added to the mandatory 90-day supply (M90) program | Farxiga; Xigduo XR |
| Drugs being added to the allowable 90-day supply (A90) program | Bromsite; Korlym |
| Removing from MHDL due to product discontinuation | Adlyxin; Aloxi; Bydureon; etidronate; Loprox 1% shampoo; Natpara; ondansetron 24 mg; Varubi injection |
Audrey Kleinberg,
Director, Provider Relations & Communications
Annmarie Dadoly,
Senior Manager, Provider Communications
Joseph O’Riordan, Susan Panos, Ellen Gustavson, Ryan Francis, Stephen Wong,
Writers
Kristin Edmonston,
Production Coordinator
Kristina Cicelova,
Graphic Designer